21 Jul 2026
Fact.MR reports that the global DLBCL therapeutics market will expand from $1.1Bn in 2026 to $2.6Bn by 2036, a 9.1% CAGR. That represents an absolute dollar opportunity of $1.5Bn. DLBCL treatment now depends more on choosing the right treatment order for each patient, with hospitals and cancer centres requiring clear guidance on when to move from chemoimmunotherapy to antibody-drug conjugates, CAR-T therapy, or bispecific antibodies.
Hospitals require clear treatment plans for higher-risk newly diagnosed patients showing when first-line chemoimmunotherapy can be paired with antibody-drug conjugates. Cancer centres benefit from a clear CAR-T referral process, since patients whose cancer returns may face delays while treatment is prepared, and bispecific antibody use requires clear steps for step-up dosing and monitoring for cytokine-release reactions across inpatient and outpatient settings.
Chemotherapy leads therapy-type demand at about 21.7%, reflecting its continued first-line chemoimmunotherapy role, while CAR-T cell therapy and bispecific antibodies address high-need relapsed cases. Newly diagnosed DLBCL leads disease-type demand at roughly 45% on its larger incident treatment pool, and intravenous delivery tops the route split at close to 38.3% across chemotherapy and antibody-based regimens. Hospitals place about 30% of end-user demand.
Germany leads at a 12.3% CAGR through 2036 on first-line regimen change and hospital depth, with Brazil close behind at 11.4% on sequencing needs after early relapse. The United States follows at 10.5% on CAR-T capacity and regulatory depth, ahead of South Korea (9.6%), the United Kingdom (8.6%), and Japan (7.7%).
CAR-T manufacturing and referral turnaround are the main brake, since autologous therapy requires patient-specific production before infusion, limiting adoption when disease progression outpaces referral completion. Toxicity management burden adds a second constraint, as cytokine-release syndrome and neurologic events require trained staff and clear escalation rules that not every hospital can support.
Roche and Bristol Myers Squibb lead direct regimen influence, with Roche39s Polivy and Columvi used at different stages of care and Bristol Myers Squibb competing through Breyanzi and its CAR-T treatment network. Gilead Sciences supports CAR-T treatment through Yescarta, while Novartis remains active through Kymriah. Competition depends on clinical results and whether treatment centres are ready to manage safety and referral logistics.
Clearly explain which newly diagnosed patients are suitable for treatment plans that include polatuzumab before expanding hospital training, and support faster CAR-T referrals with regular updates on preparation time. Train hospital staff on step-up dosing and cytokine-release monitoring before wider outpatient use, and link molecular subtype and imaging results directly to treatment choice rather than handling them as separate tasks.
Beyond the headline forecast, the Fact.MR study segments demand by therapy type, disease type, route of administration, and end user. The study also compares country-level growth across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East amp Africa from 2026 to 2036. For related analysis, see Fact.MR39s coverage of cancer therapeutics and peptide therapeutics.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Diffuse Large B-Cell Lymphoma Therapeutics Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.